Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.
AB-25E9 – bone antiresorptive
- Alethia is developing a first-in-class bone antiresorptive for the treatment of bone loss in acute disorders such a hypercalcemia of malignancy, bone and cartilage loss in inflammatory disorders and severe osteoporosis. AB-25E9 is a humanized IgG2 antibody against the cell-surface protein Siglec-15 that blocks osteoclast differentiation and function. Read more about AB-25E9
AB-3A4 – treatment of invasive carcinomas
- Alethia is developing a therapeutic monoclonal antibody for the treatment of ovarian cancer and other invasive carcinomas such as triple-negative breast tumors and renal cancer. AB-3A4 is an IgG1 monoclonal antibody against KAAG-1, a cell-surface protein involved in tumor invasion. Read more about AB-3A4
AB-16B5 – EMT inhibitor
- Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5